Clinical effect of Resina Draconis capsules on primary dysmenorrhoea
Abstract
Purpose: To examine the effectiveness of Resina Draconis capsules in the treatment of primary dysmenorrhoea.
Methods: In total, 324 patients with primary dysmenorrhoea were randomly allocated to three groups based on treatment with capsules containing Resina Draconis, Leonurus japonicus Houtt., or a placebo for 3 months. The patients’ visual analogue scale (VAS) scores and dysmenorrhoea symptoms were evaluated.
Results: VAS scores of the Resina Draconis, L. japonicus, and placebo groups decreased from 7.31 ± 1.36, 7.12 ± 1.65, and 7.25 ± 1.47 to 3.35 ± 1.43, 5.27 ± 1.24, and 7.08 ± 2.10, respectively. The change was greatest for the Resina Draconis group (p < 0.01). The incidence of symptoms associated with dysmenorrhoea decreased in all three groups, but the change was greatest for Resina Draconis group (p < 0.01). Overall, Resina Draconis was more effective than L. japonicus (94.40 vs. 72.20 %) (p < 0.05).
Conclusion: Resina Draconis capsules are effective in relieving primary dysmenorrhoea and lowering the incidence of symptoms associated with dysmenorrhoea.
Keywords: Primary dysmenorrhoea, Resina Draconis, Leonurus japonicus Houtt., Visual analogue scale
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
